Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligned with the provided FDA label excerpts: key indication core (hepatic VOD/SOS with renal or pulmonary dysfunction after HSCT), IV administration, weight-based dosing, hemorrhage and hypersensitivity warnings, and dosing schedule elements are mostly consistent. However, multiple claims are unsupported or imprecise (e.g., omission of diagnostic expertise requirement, 'severe/new-onset or worsening' and 'conditioning regimens' wording not reflected, several side effects listed without label support, and multiple mechanistic claims recharacterized beyond the provided mechanism wording).
Category Scores
Accurate Statements
Defitelio (defibrotide sodium) is indicated for treatment of adult and pediatric patients with hepatic VOD/SOS with renal or pulmonary dysfunction following HSCT.
1 INDICATIONS AND USAGE
Defitelio is administered intravenously as a 2-hour intravenous infusion.
2.1 Recommended Dosage; 2.2 Administration Instructions
Defitelio dosage should be based on the patient’s baseline body weight.
2.1 Recommended Dosage
Serious bleeding/hemorrhage is a key risk associated with Defitelio.
5.1 Hemorrhage; 6 Adverse Reactions (Hemorrhage)
Hypersensitivity reactions can occur with Defitelio.
5.2 Hypersensitivity Reactions; 6 Adverse Reactions (Hypersensitivity Reactions)
Patients should immediately report unusual bleeding or easy bruising.
17 PATIENT COUNSELING INFORMATION; 5.1 Hemorrhage
The mechanism of action is not fully elucidated.
12.1 Mechanism of Action
Defibrotide sodium is thought to improve fibrinolysis.
12.1 Mechanism of Action (increases EC-mediated fibrinolysis / enhances plasmin activity)
Bleeding risk is increased with concomitant systemic anticoagulant or fibrinolytic therapy and concomitant use is contraindicated.
5.1 Hemorrhage; 7 Drug Interactions
Unsupported Statements
Defitelio is indicated to treat severe hepatic veno-occlusive disease (VOD) (also known as sinusoidal obstruction syndrome (SOS)) in HSCT conditioning regimens.
Provided label excerpt does not include 'severe' or 'conditioning regimens'; it specifies hepatic VOD/SOS with renal or pulmonary dysfunction following HSCT.
Defitelio is indicated for adult and pediatric patients who develop severe hepatic VOD with new-onset or worsening renal or pulmonary dysfunction.
Provided label excerpt does not use 'severe' and does not explicitly state 'new-onset or worsening' renal or pulmonary dysfunction.
Defitelio should be prescribed for patients who are diagnosed by a physician experienced in treating VOD/SOS.
No such instruction is present in the provided label sections.
Defitelio is typically given as a continuous infusion over at least two hours every six hours.
Label specifies a 2-hour infusion (not 'at least' two hours).
Common side effects of Defitelio include diarrhea.
No diarrhea adverse reaction entry is provided in the available label excerpts (6 only references hemorrhage and hypersensitivity in provided material).
Common side effects of Defitelio include nausea.
No nausea adverse reaction entry is provided in the available label excerpts.
Common side effects of Defitelio include vomiting.
No vomiting adverse reaction entry is provided in the available label excerpts.
Common side effects of Defitelio include hypokalemia.
No hypokalemia adverse reaction entry is provided in the available label excerpts.
Serious side effects of Defitelio can include hypertension.
No hypertension adverse effect is provided in the available label excerpts.
Defibrotide sodium is believed to have anticoagulant properties.
Provided mechanism excerpt describes fibrinolysis/plasmin activity; it does not state 'anticoagulant properties'.
Defibrotide sodium is believed to have anti-inflammatory properties.
Provided mechanism excerpt does not characterize the drug as 'anti-inflammatory'.
Defibrotide sodium is believed to have anti-ischemic properties.
Provided mechanism excerpt does not characterize the drug as 'anti-ischemic'.
Defibrotide sodium may help restore the balance between pro-thrombotic and anti-thrombotic factors on vascular endothelium disrupted in VOD/SOS.
Provided mechanism excerpt does not include this specific 'pro-thrombotic vs anti-thrombotic balance' framing.
Defibrotide sodium is thought to inhibit platelet aggregation.
Provided mechanism excerpt does not state inhibition of platelet aggregation.
Inhibiting platelet aggregation and improving fibrinolysis may help resolve clots in hepatic sinusoidal vessels.
Provided mechanism excerpt supports fibrinolysis/increased plasmin activity but does not support 'inhibiting platelet aggregation' or 'clots in hepatic sinusoidal vessels' as stated.
Detailed prescribing information for Defitelio is available from the manufacturer and through medical resources such as the FDA's website.
No such information-source statement is present in the provided label excerpts.
Defitelio is manufactured by Jazz Pharmaceuticals.
Manufacturer information is not present in the provided label excerpts.
Defitelio's approval was based on clinical studies evaluating its impact on survival and the resolution of organ dysfunction in patients who underwent HSCT.
Provided clinical studies excerpt emphasizes survival; it does not explicitly state 'resolution of organ dysfunction' as an approval basis.
Blood pressure should be monitored during Defitelio treatment due to the risk of hypertension.
No blood pressure monitoring guidance or hypertension risk statement is provided in the available label excerpts.
Contradictions
Important Omissions
Label-supported administration safety details were not fully captured (e.g., do not co-administer in same line; use of 0.2 micron in-line filter; flush with specific solutions; confirm not experiencing clinically significant bleeding and hemodynamically stable on no more than one vasopressor prior to administration).
Importance:
Moderate
Label-supported treatment duration/modification guidance (minimum 21 days; continue until resolution up to maximum 60 days; modification for bleeding/hypersensitivity/invasive procedures) was not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are unsupported or imprecise (side effects list, mechanistic recharacterizations, hypertension monitoring), and indication wording is broadened beyond provided label excerpts ('severe', 'conditioning regimens', 'new-onset or worsening'). Some high-safety-content claims (hemorrhage, hypersensitivity, immediate reporting) are supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple unsupported/imprecise claims (especially adverse reactions and mechanistic descriptions) and indication phrasing deviations from the provided label excerpts.
Suggested Improvement
Restrict indication language to hepatic VOD/SOS with renal or pulmonary dysfunction following HSCT (as provided), remove or qualify unsupported adverse reactions and hypertension/monitoring statements unless supported by the label excerpts, and align mechanism language to the provided 'plasmin/t-PA/thrombomodulin/vWF/PAI-1' and increased fibrinolysis description rather than anticoagulant/anti-inflammatory/anti-ischemic or platelet aggregation inhibition.